Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
2.49% $6.99
America/New_York / 19 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 18.12 mill |
EPS: | -236.13 |
P/E: | -0.0300 |
Earnings Date: | May 13, 2024 |
SharesOutstanding: | 2.59 mill |
Avg Daily Volume: | 0.0780 mill |
RATING 2024-04-19 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Neutral | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | ||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0300 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.0300 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.752 (-89.25%) $-6.24 |
Date: 2024-04-20 |
Expected Trading Range (DAY) |
---|
$ 6.55 - 7.23 ( +/- 4.99%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Banks Jerel A. | Buy | 466 554 | Options (right to buy) |
2024-03-06 | Boston Megan | Buy | 200 004 | Options (right to buy) |
2023-12-06 | Smith Edward F | Buy | 35 000 | Options (right to buy) |
2023-12-06 | Francis Peter | Buy | 35 000 | Options (right to buy) |
2023-12-06 | Buchi J Kevin | Buy | 35 000 | Options (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 38 transactions |
Buy: 2 361 696 | Sell: 57 465 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.99 (2.49% ) |
Volume | 0.254 mill |
Avg. Vol. | 0.0780 mill |
% of Avg. Vol | 325.85 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.